EXELIXIS $4.58

down -0.03


22/5/2013 04:22 PM  |  NASDAQ : EXEL  |  Industries : Professional, Scientific, and Technical Services / Scientific Research and Development Services
12 Mo. Price Change : -5% - EXEL has underperformed the S&P 500 by 31%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga

  2. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus

  3. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in ...

    Benzinga

  4. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FOXBusiness

  5. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga

  6. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga

  7. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga

  8. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FOXBusiness

  9. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga

  10. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    At Market Intelligence Center

  11. Health Care Sector Wrap

    FOXBusiness

  12. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FOXBusiness

  13. Interpublic Group, Exelixis Gapping Down Monday

    FOXBusiness

  14. UPDATE: Exelixis Announces Proposed Convertible Debt Offering of ...

    Benzinga

  15. Exelixis Proposed Offering 20M Shares

    Benzinga

  16. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus

  17. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga

  18. Benzinga's Top Pre-Market Gainers

    Benzinga

  19. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga

  20. Exelixis Announces Initiation of Cabozantinib ...

    Benzinga

  21. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga

  22. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga

  23. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga

  24. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in ...

    Benzinga

  25. Exelixis Completes Submission of New Drug Application for ...

    Benzinga

  26. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall ...

    Benzinga

  27. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga

  28. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    at Benzinga

  29. 5 Resilient Biotech Stocks to Buy for 2012

    at GuruFocus

  30. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    at Benzinga

  31. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    At Market Intelligence Center

  32. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    at Benzinga

  33. Exelixis Announces Proposed Public Offering of 10M Shares

    at Benzinga

  34. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in ...

    at Benzinga

  35. Notable Call Options Activity on Exelixis

    at Benzinga

  36. Exelixis Trading Higher After Licensing Agreement with Merck

    at Benzinga

  37. Exelixis Lures Premium Sellers on Positive Drug Data

    By SchaeffersResearch
People viewing EXEL also viewed: , , , , , ,
Marketplace
Trading Center